CMS has selected an additional 15 high-cost drugs for the third round of Medicare Drug Price Negotiation Program negotiations.[1][3] These drugs are covered by Medicare Parts B and D and were expected to account for $27 billion in spending between November 2024 and October 2025.[user] The selection includes both Part D and Part B drugs, the first inclusion of Part B drugs in the program.[1][4] CMS will announce a list of these 15 drugs by February 1, 2026, along with drugs for renegotiation from previous cycles.[1][3][4] The third round of negotiations will take place in 2026 and the negotiated maximum fair prices (MFP) will enter into force on 1 January 2028.[1][3] The program prioritizes high-cost drugs for Medicare, improves transparency, and minimizes the negative impact on pharmaceutical innovation.[1] A second cycle for 15 Part D drugs takes place in 2025 with prices effective from 2027.[2][5]